Header Logo

Connection

THOMAS WHEELER to Male

Back to Details
This is a "connection" page, showing publications THOMAS WHEELER has written about Male.
THOMAS WHEELER
Connection Strength
0.803
Male
  1. Editorial Comment. J Urol. 2017 12; 198(6):1323.
    View in: PubMed
    Score: 0.022
  2. Metabolomic signatures of aggressive prostate cancer. Prostate. 2013 Oct; 73(14):1547-60.
    View in: PubMed
    Score: 0.017
  3. Desquamating apoptotic variant of high-grade prostatic intraepithelial neoplasia: a possible precursor of intraductal prostatic carcinoma. Hum Pathol. 2011 Jun; 42(6):892-5.
    View in: PubMed
    Score: 0.014
  4. Ductal adenocarcinoma of the prostate. Hum Pathol. 2011 Apr; 42(4):605-6; author reply 606-7.
    View in: PubMed
    Score: 0.014
  5. Significance of the craniocaudal distribution of cancer in radical prostatectomy specimens. Int J Urol. 2007 Sep; 14(9):817-21.
    View in: PubMed
    Score: 0.011
  6. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun; 37(6):726-34.
    View in: PubMed
    Score: 0.010
  7. Bystin in perineural invasion of prostate cancer. Prostate. 2006 Feb 15; 66(3):266-72.
    View in: PubMed
    Score: 0.010
  8. Radical prostatectomy for carcinoma of the prostate. Mod Pathol. 2004 Mar; 17(3):349-59.
    View in: PubMed
    Score: 0.009
  9. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J. 2003 Nov-Dec; 9(6):454-60.
    View in: PubMed
    Score: 0.009
  10. Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible? J Urol. 2003 Mar; 169(3):964-8.
    View in: PubMed
    Score: 0.008
  11. Low-grade prostate cancer should still be labelled cancer. BJU Int. 2022 12; 130(6):741-743.
    View in: PubMed
    Score: 0.008
  12. Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol. 2001 Nov; 25(11):1429-32.
    View in: PubMed
    Score: 0.007
  13. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol. 2001 Aug; 32(8):828-33.
    View in: PubMed
    Score: 0.007
  14. ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. Am J Surg Pathol. 2021 08 01; 45(8):1118-1126.
    View in: PubMed
    Score: 0.007
  15. Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol. 2001 May; 25(5):657-60.
    View in: PubMed
    Score: 0.007
  16. Aspiration fluid cytology during single operator cholangioscopy with targeted biopsy to improves the diagnostic yield in indeterminate biliary strictures. Diagn Cytopathol. 2021 Jun; 49(6):768-772.
    View in: PubMed
    Score: 0.007
  17. Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. Ann Diagn Pathol. 2021 Jun; 52:151733.
    View in: PubMed
    Score: 0.007
  18. Verumontanum mucosal gland hyperplasia is associated with atypical adenomatous hyperplasia of the prostate. Arch Pathol Lab Med. 2001 Mar; 125(3):358-60.
    View in: PubMed
    Score: 0.007
  19. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. Cancer Res. 2000 Dec 15; 60(24):7142-8.
    View in: PubMed
    Score: 0.007
  20. Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. Eur Urol Focus. 2021 09; 7(5):955-963.
    View in: PubMed
    Score: 0.007
  21. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020 08; 44(8):e87-e99.
    View in: PubMed
    Score: 0.007
  22. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol. 2000 Jun; 24(6):859-63.
    View in: PubMed
    Score: 0.007
  23. Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. Am J Surg Pathol. 1999 Aug; 23(8):932-6.
    View in: PubMed
    Score: 0.006
  24. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol. 1999 Aug; 12(8):751-5.
    View in: PubMed
    Score: 0.006
  25. Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Arch. 2019 Sep; 475(3):263-277.
    View in: PubMed
    Score: 0.006
  26. The association of selected pathological features with prostate cancer in a single-needle biopsy accession. Hum Pathol. 1998 Dec; 29(12):1536-8.
    View in: PubMed
    Score: 0.006
  27. Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology. 2019 Jan; 51(1):11-20.
    View in: PubMed
    Score: 0.006
  28. Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. Hum Pathol. 1998 Oct; 29(10):1119-23.
    View in: PubMed
    Score: 0.006
  29. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998 Aug; 29(8):856-62.
    View in: PubMed
    Score: 0.006
  30. The significance of intraluminal prostatic crystalloids in benign needle biopsies. Am J Surg Pathol. 1998 Apr; 22(4):446-9.
    View in: PubMed
    Score: 0.006
  31. Distribution and significance of microcalcifications in the neoplastic and nonneoplastic prostate. Arch Pathol Lab Med. 1998 Feb; 122(2):152-5.
    View in: PubMed
    Score: 0.006
  32. Immunohistochemical and ultrastructural study of rhabdosphincter component of the prostatic capsule. J Urol. 1997 Nov; 158(5):1819-28.
    View in: PubMed
    Score: 0.006
  33. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Ann Thorac Surg. 2017 Nov; 104(5):1679-1687.
    View in: PubMed
    Score: 0.006
  34. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 07 13; 377(2):132-142.
    View in: PubMed
    Score: 0.006
  35. The striated urethral sphincter: muscle fibre types and distribution in the prostatic capsule. Br J Urol. 1997 Apr; 79(4):539-42.
    View in: PubMed
    Score: 0.005
  36. Morphometric analysis of calcification and fibrous layer thickness in carotid endarterectomy tissues. Comput Biol Med. 2016 Mar 01; 70:210-219.
    View in: PubMed
    Score: 0.005
  37. Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. Eur Urol. 1996; 30(2):261-4.
    View in: PubMed
    Score: 0.005
  38. Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Hum Pathol. 1995 Dec; 26(12):1341-6.
    View in: PubMed
    Score: 0.005
  39. High grade prostatic intraepithelial neoplasia in prostates removed following irradiation failure in the treatment of prostatic adenocarcinoma. Pathol Res Pract. 1995 Sep; 191(9):868-72.
    View in: PubMed
    Score: 0.005
  40. Pelvic lymph node histiocytosis mimicking metastatic prostatic adenocarcinoma: association with hip prostheses. J Urol. 1995 Aug; 154(2 Pt 1):470-3.
    View in: PubMed
    Score: 0.005
  41. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol. 1995 Aug; 19(8):873-86.
    View in: PubMed
    Score: 0.005
  42. Verumontanum mucosal gland hyperplasia. Am J Surg Pathol. 1995 Jan; 19(1):30-6.
    View in: PubMed
    Score: 0.005
  43. Active surveillance for prostate cancer: the role of the pathologist. Pathology. 2015 Jan; 47(1):1-3.
    View in: PubMed
    Score: 0.005
  44. Fresh tissue harvest for research from prostatectomy specimens. Prostate. 1994 Nov; 25(5):274-9.
    View in: PubMed
    Score: 0.005
  45. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch. 2014 Dec; 465(6):623-8.
    View in: PubMed
    Score: 0.005
  46. DNA ploidy measurements in prostate cancer: differences between image analysis and flow cytometry and clinical implications. Prostate. 1994 Oct; 25(4):189-98.
    View in: PubMed
    Score: 0.005
  47. Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Ann Diagn Pathol. 2014 Dec; 18(6):333-42.
    View in: PubMed
    Score: 0.005
  48. Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy. J Urol. 2015 Jan; 193(1):58-63.
    View in: PubMed
    Score: 0.004
  49. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med. 2014 Oct; 138(10):1387-405.
    View in: PubMed
    Score: 0.004
  50. Tamm-Horsfall protein in bladder tissue. Morphologic spectrum and clinical significance. Am J Surg Pathol. 1994 Jun; 18(6):615-22.
    View in: PubMed
    Score: 0.004
  51. Recruitment of CD34(+) fibroblasts in tumor-associated reactive stroma: the reactive microvasculature hypothesis. Am J Pathol. 2014 Jun; 184(6):1860-70.
    View in: PubMed
    Score: 0.004
  52. Paraganglia of the prostate. Location, frequency, and differentiation from prostatic adenocarcinoma. Am J Surg Pathol. 1994 Apr; 18(4):412-20.
    View in: PubMed
    Score: 0.004
  53. Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol. 2014 Jul; 45(7):1365-9.
    View in: PubMed
    Score: 0.004
  54. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. J Cell Biochem Suppl. 1994; 19:202-7.
    View in: PubMed
    Score: 0.004
  55. Clinical relevance of the individual prostate cancer focus. Cancer Invest. 1994; 12(4):425-37.
    View in: PubMed
    Score: 0.004
  56. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol. 1993 Dec; 17(12):1252-61.
    View in: PubMed
    Score: 0.004
  57. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr; 32(2):235-242.
    View in: PubMed
    Score: 0.004
  58. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun; 189(6):2039-46.
    View in: PubMed
    Score: 0.004
  59. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting. Histopathology. 2013 Jan; 62(2):203-18.
    View in: PubMed
    Score: 0.004
  60. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn. 2013 Mar; 15(2):270-9.
    View in: PubMed
    Score: 0.004
  61. Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer? Prostate. 2013 Mar; 73(4):442-8.
    View in: PubMed
    Score: 0.004
  62. Do adenocarcinomas of the prostate with Gleason score (GS) =6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012 Sep; 36(9):1346-52.
    View in: PubMed
    Score: 0.004
  63. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
    View in: PubMed
    Score: 0.004
  64. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol. 2011 Jul; 136(1):98-107.
    View in: PubMed
    Score: 0.004
  65. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int. 2011 Oct; 108(7):1074-85.
    View in: PubMed
    Score: 0.004
  66. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87.
    View in: PubMed
    Score: 0.003
  67. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol. 2011 Jan; 24(1):6-15.
    View in: PubMed
    Score: 0.003
  68. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011 Jan; 24(1):16-25.
    View in: PubMed
    Score: 0.003
  69. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol. 2011 Jan; 24(1):39-47.
    View in: PubMed
    Score: 0.003
  70. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011 Jan; 24(1):26-38.
    View in: PubMed
    Score: 0.003
  71. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011 Jan; 24(1):48-57.
    View in: PubMed
    Score: 0.003
  72. A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis. BJU Int. 2011 Feb; 107(3):389-95.
    View in: PubMed
    Score: 0.003
  73. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010 Jul; 184(1):149-56.
    View in: PubMed
    Score: 0.003
  74. Thymic carcinoma. A clinicopathologic study of 13 cases. Am J Surg Pathol. 1990 Feb; 14(2):151-66.
    View in: PubMed
    Score: 0.003
  75. Pathologic basis of the sonographic appearance of the normal and malignant prostate. Urol Clin North Am. 1989 Nov; 16(4):675-91.
    View in: PubMed
    Score: 0.003
  76. Anatomic considerations in carcinoma of the prostate. Urol Clin North Am. 1989 Nov; 16(4):623-34.
    View in: PubMed
    Score: 0.003
  77. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med. 2009 Oct; 133(10):1568-76.
    View in: PubMed
    Score: 0.003
  78. Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Res. 2009 Jun; 29(6):2077-81.
    View in: PubMed
    Score: 0.003
  79. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Clin Cancer Res. 2009 May 15; 15(10):3568-73.
    View in: PubMed
    Score: 0.003
  80. The genome sequence of taurine cattle: a window to ruminant biology and evolution. Science. 2009 Apr 24; 324(5926):522-8.
    View in: PubMed
    Score: 0.003
  81. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology. 2009 Apr; 251(1):122-33.
    View in: PubMed
    Score: 0.003
  82. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603.
    View in: PubMed
    Score: 0.003
  83. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology. 2008 Dec; 72(6 Suppl):S12-24.
    View in: PubMed
    Score: 0.003
  84. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.003
  85. Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol. 2008 Oct; 32(10):1503-12.
    View in: PubMed
    Score: 0.003
  86. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol. 2008 Oct; 32(10):1532-9.
    View in: PubMed
    Score: 0.003
  87. The sensitivity of detection of asbestos bodies in sputa and bronchial washings. Acta Cytol. 1988 Sep-Oct; 32(5):647-50.
    View in: PubMed
    Score: 0.003
  88. Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. J Urol. 2008 May; 179(5):1762-7; discussion 1767.
    View in: PubMed
    Score: 0.003
  89. Malignant advanced granulosa cell tumor of the adult testis: case report and review of the literature. Hum Pathol. 2008 May; 39(5):701-9.
    View in: PubMed
    Score: 0.003
  90. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology. 2008 Jun; 71(6):1166-71.
    View in: PubMed
    Score: 0.003
  91. Isolated renal artery dissection secondary to medial degeneration. J Urol. 1988 Feb; 139(2):346-7.
    View in: PubMed
    Score: 0.003
  92. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr. 1988; (7):95-103.
    View in: PubMed
    Score: 0.003
  93. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007 Dec 01; 13(23):6947-58.
    View in: PubMed
    Score: 0.003
  94. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology. 2007 Nov; 70(5):965-9.
    View in: PubMed
    Score: 0.003
  95. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
    View in: PubMed
    Score: 0.003
  96. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20.
    View in: PubMed
    Score: 0.003
  97. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007 Nov; 38(11):1688-95.
    View in: PubMed
    Score: 0.003
  98. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest. 2007 Jul; 117(7):1876-83.
    View in: PubMed
    Score: 0.003
  99. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res. 2007 Jul 01; 13(13):3796-802.
    View in: PubMed
    Score: 0.003
  100. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch Pathol Lab Med. 2007 Jul; 131(7):1103-9.
    View in: PubMed
    Score: 0.003
  101. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol. 2007 Oct; 38(10):1501-7.
    View in: PubMed
    Score: 0.003
  102. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007 Feb 01; 25(4):349-55.
    View in: PubMed
    Score: 0.003
  103. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol. 2006 Sep; 176(3):991-5.
    View in: PubMed
    Score: 0.003
  104. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.003
  105. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med. 2006 Jul; 130(7):936-46.
    View in: PubMed
    Score: 0.003
  106. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 2006 May 15; 66(10):5159-64.
    View in: PubMed
    Score: 0.003
  107. Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate. J Urol. 2006 Mar; 175(3 Pt 1):923-7; discussion 927-8.
    View in: PubMed
    Score: 0.003
  108. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
    View in: PubMed
    Score: 0.002
  109. Biological correlates of p27 compartmental expression in prostate cancer. J Urol. 2006 Feb; 175(2):528-32.
    View in: PubMed
    Score: 0.002
  110. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36.
    View in: PubMed
    Score: 0.002
  111. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 2006 Feb 01; 66(3):1880; author reply 1880-1.
    View in: PubMed
    Score: 0.002
  112. A cancer DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci U S A. 2005 Dec 27; 102(52):19093-6.
    View in: PubMed
    Score: 0.002
  113. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 01; 65(3):276-86.
    View in: PubMed
    Score: 0.002
  114. Neuroanatomy of the normal prostate. Prostate. 2005 Sep 15; 65(1):52-7.
    View in: PubMed
    Score: 0.002
  115. Visceral pericardial hemangioma: unusual location for a rare cardiac tumor. J Am Soc Echocardiogr. 2005 Sep; 18(9):981.
    View in: PubMed
    Score: 0.002
  116. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl. 2005 May; (216):8-19.
    View in: PubMed
    Score: 0.002
  117. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl. 2005 May; (216):20-33.
    View in: PubMed
    Score: 0.002
  118. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005 May; (216):34-63.
    View in: PubMed
    Score: 0.002
  119. Thyroid fine-needle aspiration biopsy in children and adolescents: experience with 218 aspirates. Diagn Cytopathol. 2005 Apr; 32(4):189-92.
    View in: PubMed
    Score: 0.002
  120. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005 Mar 15; 103(6):1186-94.
    View in: PubMed
    Score: 0.002
  121. Prostatic biopsy after irradiation therapy for prostatic cancer. Urology. 1985 Feb; 25(2 Suppl):39-46.
    View in: PubMed
    Score: 0.002
  122. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18.
    View in: PubMed
    Score: 0.002
  123. Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate. 2004 Oct 01; 61(2):182-91.
    View in: PubMed
    Score: 0.002
  124. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004 Oct 01; 10(19):6572-8.
    View in: PubMed
    Score: 0.002
  125. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol. 2004 Sep; 172(3):900-4.
    View in: PubMed
    Score: 0.002
  126. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 2004 Sep 01; 64(17):6082-90.
    View in: PubMed
    Score: 0.002
  127. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol. 2004 Aug; 172(2):508-11.
    View in: PubMed
    Score: 0.002
  128. Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. Proc Natl Acad Sci U S A. 2004 Aug 03; 101(31):11428-31.
    View in: PubMed
    Score: 0.002
  129. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol. 2004 Jul; 28(7):928-34.
    View in: PubMed
    Score: 0.002
  130. Intratesticular adenomatoid tumor radiographically mimicking a primary testicular malignancy. ScientificWorldJournal. 2004 Jun 07; 4 Suppl 1:11-5.
    View in: PubMed
    Score: 0.002
  131. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
    View in: PubMed
    Score: 0.002
  132. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004 Jun; 63(6):1191-7.
    View in: PubMed
    Score: 0.002
  133. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol. 2004 May; 171(5):1844-9; discussion 1849.
    View in: PubMed
    Score: 0.002
  134. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol. 2004 May; 171(5):1850-4.
    View in: PubMed
    Score: 0.002
  135. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004 May 01; 22(9):1655-63.
    View in: PubMed
    Score: 0.002
  136. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
    View in: PubMed
    Score: 0.002
  137. Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res. 2004 Mar 15; 64(6):2076-82.
    View in: PubMed
    Score: 0.002
  138. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004 Mar 15; 10(6):1992-9.
    View in: PubMed
    Score: 0.002
  139. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol. 2004 Mar; 171(3):1089-92.
    View in: PubMed
    Score: 0.002
  140. Recurrent hypercalcemia due to ectopic production of parathyroid hormone-related protein and intact parathyroid hormone in a single patient with multiple malignancies. Endocr Pract. 2004 Mar-Apr; 10(2):125-8.
    View in: PubMed
    Score: 0.002
  141. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate. 2004 Feb 01; 58(2):193-9.
    View in: PubMed
    Score: 0.002
  142. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol. 2004 Jan; 171(1):200-3.
    View in: PubMed
    Score: 0.002
  143. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol. 2004 Jan; 171(1):204-9.
    View in: PubMed
    Score: 0.002
  144. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003 Dec; 170(6 Pt 1):2248-52.
    View in: PubMed
    Score: 0.002
  145. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003 Dec; 170(6 Pt 1):2292-5.
    View in: PubMed
    Score: 0.002
  146. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003 Nov; 170(5):1792-7.
    View in: PubMed
    Score: 0.002
  147. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4792-801.
    View in: PubMed
    Score: 0.002
  148. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol. 2003 Oct; 170(4 Pt 1):1203-8.
    View in: PubMed
    Score: 0.002
  149. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003 Oct 01; 63(19):6244-51.
    View in: PubMed
    Score: 0.002
  150. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res. 2003 Sep 15; 63(18):5874-8.
    View in: PubMed
    Score: 0.002
  151. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3653-9.
    View in: PubMed
    Score: 0.002
  152. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003 Oct 01; 21(19):3573-9.
    View in: PubMed
    Score: 0.002
  153. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003 Aug 01; 63(15):4662-70.
    View in: PubMed
    Score: 0.002
  154. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res. 2003 Jul-Aug; 23(4):3413-8.
    View in: PubMed
    Score: 0.002
  155. IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):184-91.
    View in: PubMed
    Score: 0.002
  156. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003 May; 61(5):1053-8.
    View in: PubMed
    Score: 0.002
  157. Neural cell adhesion molecule is upregulated in nerves with prostate cancer invasion. Hum Pathol. 2003 May; 34(5):457-61.
    View in: PubMed
    Score: 0.002
  158. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci U S A. 2003 Apr 29; 100(9):5401-6.
    View in: PubMed
    Score: 0.002
  159. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol. 2003 Apr 01; 21(7):1223-31.
    View in: PubMed
    Score: 0.002
  160. Neuroepithelial interactions in prostate cancer are enhanced in the presence ofprostatic stroma. Urology. 2003 Apr; 61(4):870-5.
    View in: PubMed
    Score: 0.002
  161. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
    View in: PubMed
    Score: 0.002
  162. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
    View in: PubMed
    Score: 0.002
  163. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol. 2002 Nov; 168(5):2011-5.
    View in: PubMed
    Score: 0.002
  164. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002 Nov; 8(11):3419-26.
    View in: PubMed
    Score: 0.002
  165. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002 Oct 15; 62(20):5974-9.
    View in: PubMed
    Score: 0.002
  166. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96.
    View in: PubMed
    Score: 0.002
  167. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification]. Nihon Hinyokika Gakkai Zasshi. 2002 Jul; 93(5):595-601.
    View in: PubMed
    Score: 0.002
  168. Granulomatous infections complicating hairy cell leukemia. Cancer. 1982 May 01; 49(9):1924-8.
    View in: PubMed
    Score: 0.002
  169. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? J Clin Oncol. 2002 Apr 15; 20(8):2025-30.
    View in: PubMed
    Score: 0.002
  170. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 2002 Mar; 167(3):1475-81.
    View in: PubMed
    Score: 0.002
  171. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002 Feb; 167(2 Pt 1):528-34.
    View in: PubMed
    Score: 0.002
  172. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002 Feb 01; 20(3):833-41.
    View in: PubMed
    Score: 0.002
  173. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
    View in: PubMed
    Score: 0.002
  174. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15; 92(12):2985-92.
    View in: PubMed
    Score: 0.002
  175. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001 Dec; 58(6):1008-15.
    View in: PubMed
    Score: 0.002
  176. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
    View in: PubMed
    Score: 0.002
  177. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
    View in: PubMed
    Score: 0.002
  178. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate. 2001 Nov 01; 49(3):213-23.
    View in: PubMed
    Score: 0.002
  179. Age-related radical-induced DNA damage is linked to prostate cancer. Cancer Res. 2001 Aug 15; 61(16):6025-8.
    View in: PubMed
    Score: 0.002
  180. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia. 2001 Jul-Aug; 3(4):287-303.
    View in: PubMed
    Score: 0.002
  181. Bilateral nerve graft during radical retropubic prostatectomy: 1-year followup. J Urol. 2001 Jun; 165(6 Pt 1):1950-6.
    View in: PubMed
    Score: 0.002
  182. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001 Jun 01; 19(11):2856-64.
    View in: PubMed
    Score: 0.002
  183. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
    View in: PubMed
    Score: 0.002
  184. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001 May; 165(5):1554-9.
    View in: PubMed
    Score: 0.002
  185. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95.
    View in: PubMed
    Score: 0.002
  186. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001 Feb 15; 19(4):1030-9.
    View in: PubMed
    Score: 0.002
  187. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001 Jan 15; 61(2):497-503.
    View in: PubMed
    Score: 0.002
  188. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
    View in: PubMed
    Score: 0.002
  189. Leptin and prostate cancer. Prostate. 2001 Jan 01; 46(1):62-7.
    View in: PubMed
    Score: 0.002
  190. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol. 2001 Jan; 32(1):74-80.
    View in: PubMed
    Score: 0.002
  191. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000 Dec; 164(6):1929-34.
    View in: PubMed
    Score: 0.002
  192. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
    View in: PubMed
    Score: 0.002
  193. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000 Oct 15; 60(20):5857-61.
    View in: PubMed
    Score: 0.002
  194. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology. 2000 Sep 01; 56(3):423-9.
    View in: PubMed
    Score: 0.002
  195. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res. 2000 Sep; 6(9):3430-3.
    View in: PubMed
    Score: 0.002
  196. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70.
    View in: PubMed
    Score: 0.002
  197. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene. 2000 Apr 27; 19(18):2186-93.
    View in: PubMed
    Score: 0.002
  198. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000 Feb 01; 60(3):756-9.
    View in: PubMed
    Score: 0.002
  199. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol. 2000 Jan; 18(1):116-21.
    View in: PubMed
    Score: 0.002
  200. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology. 2000 Jan; 55(1):41-5.
    View in: PubMed
    Score: 0.002
  201. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999 Nov 15; 59(22):5719-23.
    View in: PubMed
    Score: 0.002
  202. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
    View in: PubMed
    Score: 0.002
  203. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999 May; 17(5):1499-507.
    View in: PubMed
    Score: 0.002
  204. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999 May 01; 10(7):1239-49.
    View in: PubMed
    Score: 0.002
  205. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 1999 Feb; 161(2):500-4.
    View in: PubMed
    Score: 0.002
  206. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol. 1999 Jan; 161(1):188-92.
    View in: PubMed
    Score: 0.002
  207. Elastic moduli of breast and prostate tissues under compression. Ultrason Imaging. 1998 Oct; 20(4):260-74.
    View in: PubMed
    Score: 0.001
  208. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998 Aug; 4(8):1873-80.
    View in: PubMed
    Score: 0.001
  209. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol. 1998 Jun; 159(6):2220-5.
    View in: PubMed
    Score: 0.001
  210. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998 May 20; 90(10):766-71.
    View in: PubMed
    Score: 0.001
  211. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res. 1998 Mar 15; 58(6):1285-90.
    View in: PubMed
    Score: 0.001
  212. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998 Jan 01; 82(1):168-75.
    View in: PubMed
    Score: 0.001
  213. In situ end-labeling of human testicular tissue demonstrates increased apoptosis in conditions of abnormal spermatogenesis. Fertil Steril. 1997 Dec; 68(6):1065-9.
    View in: PubMed
    Score: 0.001
  214. Apoptotic frequency is increased in spermatogenic maturation arrest and hypospermatogenic states. J Urol. 1997 Nov; 158(5):1791-3.
    View in: PubMed
    Score: 0.001
  215. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res. 1997 Aug; 3(8):1389-97.
    View in: PubMed
    Score: 0.001
  216. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997 Jul; 50(1):93-9.
    View in: PubMed
    Score: 0.001
  217. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol. 1997 Jun; 157(6):2212-8.
    View in: PubMed
    Score: 0.001
  218. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 1997 Feb 01; 79(3):528-37.
    View in: PubMed
    Score: 0.001
  219. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer. 1996 Sep 15; 78(6):1267-71.
    View in: PubMed
    Score: 0.001
  220. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 1996 Sep; 156(3):1059-63.
    View in: PubMed
    Score: 0.001
  221. Staging and reporting of prostate cancer--sampling of the radical prostatectomy specimen. Cancer. 1996 Jul 15; 78(2):366-8.
    View in: PubMed
    Score: 0.001
  222. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996 Jul; 48(1):47-57.
    View in: PubMed
    Score: 0.001
  223. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res. 1996 Apr; 2(4):635-40.
    View in: PubMed
    Score: 0.001
  224. Impalpable prostate cancer: clinicopathological features. Br J Urol. 1996 Mar; 77(3):429-32.
    View in: PubMed
    Score: 0.001
  225. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res. 1996 Feb; 2(2):399-401.
    View in: PubMed
    Score: 0.001
  226. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer. 1995 Dec 15; 76(12):2530-4.
    View in: PubMed
    Score: 0.001
  227. Verumontanum mucosal gland hyperplasia in prostatic needle biopsy specimens. A mimic of low grade prostatic adenocarcinoma. Am J Clin Pathol. 1995 Dec; 104(6):620-6.
    View in: PubMed
    Score: 0.001
  228. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995 Nov; 154(5):1818-24.
    View in: PubMed
    Score: 0.001
  229. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res. 1995 Oct; 1(10):1111-8.
    View in: PubMed
    Score: 0.001
  230. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer. 1995 Jan 15; 75(2):522-9.
    View in: PubMed
    Score: 0.001
  231. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995 Jan; 153(1):104-10.
    View in: PubMed
    Score: 0.001
  232. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994 Nov; 152(5 Pt 2):1714-20.
    View in: PubMed
    Score: 0.001
  233. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov; 152(5 Pt 2):1843-9.
    View in: PubMed
    Score: 0.001
  234. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol. 1994 Aug; 25(8):797-801.
    View in: PubMed
    Score: 0.001
  235. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer. 1994 Jul 01; 74(1):104-14.
    View in: PubMed
    Score: 0.001
  236. Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer. Br J Urol. 1994 Jul; 74(1):72-9.
    View in: PubMed
    Score: 0.001
  237. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol. 1994 Jun; 151(6):1558-64.
    View in: PubMed
    Score: 0.001
  238. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol. 1994 May; 151(5):1301-7.
    View in: PubMed
    Score: 0.001
  239. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl. 1994; 19:283-9.
    View in: PubMed
    Score: 0.001
  240. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology. 1994 Jan; 43(1):60-6; discussion 66-7.
    View in: PubMed
    Score: 0.001
  241. Ultrasonic detection of non-palpable seminal vesicle invasion: a clinicopathological study. Br J Urol. 1993 Nov; 72(5 Pt 2):799-808.
    View in: PubMed
    Score: 0.001
  242. Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation. Prostate. 1993; 23(4):271-81.
    View in: PubMed
    Score: 0.001
  243. Sonographic monitoring of prostate cancer after definitive radiotherapy. Urology. 1992 Sep; 40(3):230-6.
    View in: PubMed
    Score: 0.001
  244. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol. 1992 Aug; 148(2 Pt 1):331-7.
    View in: PubMed
    Score: 0.001
  245. Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy. Urology. 1992 Apr; 39(4):358-63.
    View in: PubMed
    Score: 0.001
  246. Unusual hyperechoic appearance of prostate cancer on transrectal ultrasonography. Br J Urol. 1992 Feb; 69(2):169-74.
    View in: PubMed
    Score: 0.001
  247. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol. 1991 Nov; 68(5):499-509.
    View in: PubMed
    Score: 0.001
  248. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol. 1991 Oct; 146(4):1069-76.
    View in: PubMed
    Score: 0.001
  249. DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. Cancer Res. 1991 Aug 01; 51(15):4084-9.
    View in: PubMed
    Score: 0.001
  250. Transrectal ultrasonography in stage A prostate cancer: detection of residual tumor after transurethral resection of prostate. J Urol. 1991 Aug; 146(2):366-71.
    View in: PubMed
    Score: 0.001
  251. The sonographic appearance of irradiated prostate cancer. Br J Urol. 1991 Aug; 68(2):172-7.
    View in: PubMed
    Score: 0.001
  252. The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol. 1991 Feb; 145(2):324-8; discussion 328-9.
    View in: PubMed
    Score: 0.001
  253. Staging of prostate cancer. Value of ultrasonography. Urol Clin North Am. 1989 Nov; 16(4):713-34.
    View in: PubMed
    Score: 0.001
  254. Ultrasonographic changes in the normal and malignant prostate after definitive radiotherapy. Urol Clin North Am. 1989 Nov; 16(4):741-9.
    View in: PubMed
    Score: 0.001
  255. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol. 1989 Jul; 142(1):76-82.
    View in: PubMed
    Score: 0.001
  256. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol. 1988 Sep; 140(3):544-9.
    View in: PubMed
    Score: 0.001
  257. Testicular metastasis as the first manifestation of colon carcinoma. J Urol. 1988 Sep; 140(3):621-2.
    View in: PubMed
    Score: 0.001
  258. Acquired cystic kidney disease: occurrence in patients on chronic peritoneal dialysis. Am J Kidney Dis. 1988 Feb; 11(2):192-5.
    View in: PubMed
    Score: 0.001
  259. The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol. 1986 Mar; 135(3):510-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.